Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The 2025 Annual Meeting of the American Academy of Neurology (AAN) will be held in San Diego, California, on April 5-9. The conference will feature clinical, poster, and scientific sessions, as well as plenary sessions on the latest research news in neurology presented by leading researchers in the field. In the myasthenia gravis (MG) setting, presentations will include an overview of MG, complement and FcRn inhibitors, and a clinical case discussion. The 2025 AAN Annual Meeting is set to be a pivotal event, gathering top experts to present cutting-edge research and innovations that will define the future of neurology.
Nicholas J. Silvestri, MD
Professor, Department of Neurology, University at Buffalo Jacobs School of Medicine & Biomedical Sciences; Staff Physician, UBMD, Buffalo, New York
“This has been a very exciting time in the field of MG for the past several years. We've seen some great data released at previous AAN meetings, as well as AANEM meetings. And I have every expectation that we'll see some excellent stuff presented over the course of the week in San Diego.”
Preconference Considerations
AAN 2025: Anticipating New Approaches in Myasthenia
Dr Silvestri speculates that the upcoming American Academy of Neurology Annual Meeting will highlight recent advancements in myasthenia gravis (MG) treatments, including open-label extension data for agents such as efgartigimod and rozanolixizumab. New therapies such as FcRn antagonists nipocalimab and batoclimab and B-cell therapies such as inebilizumab are also expected to be discussed, along with CAR T therapy programs. The meeting will provide valuable insights into long-term efficacy, safety, and real-world experiences with MG treatments, continuing the momentum in this rapidly evolving field.
Quick Clinical Takeaways
Coming soon: Dr Silvestri highlights new data and progress regarding myasthenia gravis immediately following AAN.
How Will My Patients Benefit?
Coming soon: Dr Silvestri reflects on how new data from AAN will affect his patients with myasthenia gravis.
